What We May Expect from Biomarkers in Heart Failure

Heart Failure Clinics

Volumn 5, Issue 4, 2009, Pages 463-470

  Richards, A Mark ^a,b  

^a National Heart Foundation   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Biomarkers; Diagnosis; Heart failure; Monitoring; Prognosis; Treatment

Indexed keywords

ADRENALIN; ADRENOMEDULLIN; ALDOSTERONE; ANGIOTENSIN II; ARGIPRESSIN; BIG ENDOTHELIN 1; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE MB; ENDOTHELIN 1; FAS ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; MYOSIN LIGHT CHAIN KINASE; NATRIURETIC PEPTIDE TYPE C; NORADRENALIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UROCORTIN I; UROCORTIN II; UROCORTIN III;

DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; HEART FAILURE; HEART VENTRICLE REMODELING; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS;

EID: 67650646481     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2009.04.011     Document Type: Review

References (33)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med 358 (2008) 2148-2159
2. Morrow D.A., and de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 (2007) 949-952
3. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
4. Latini R., Masson S., Anand I., et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 (2004) 292-299
5. Kiowski W., Kim J., Oechslin E., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346 (1995) 732-736
6. Rademaker M.T., Charles C.J., Lewis L.K., et al. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 96 (1997) 1983-1990
7. Rademaker M.T., Charles C.J., Espiner E.A., et al. Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 26 (2005) 2046-2054
8. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
9. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 223 (1990) 236-241
10. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
11. Anker S.D., and von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 90 (2004) 464-470
12. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
13. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
14. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107 (2003) 721-726
15. Januzzi Jr. J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50 (2007) 607-613
16. Molyneux S.L., Florkowski C.M., George P.M., et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol 52 (2008) 1435-1441
17. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50 (2007) 1054-1060
18. van Kimmenade R.R., Januzzi J.J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48 (2006) 1217-1224
19. Omland T., Drazner M.H., Ueland T., et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 49 (2007) 1392-1398
20. Richards A.M., and Charles C. Urotensin II in the cardiovascular system. Peptides 25 (2004) 1795-1802
21. Troughton R.W., and Richards A.M. Outpatient monitoring and treatment of chronic heart failure guided by NT-proBNP measurement. Am J Cardiol 101 Suppl (2008) 72A-75A
22. Francis G.S., Cohn J.N., Johnson G., et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 87 (1993) VI40-VI48
23. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000) 2700-2706
24. Richards A.M., Doughty R., Nicholls M.G., et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
25. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
26. Goldstein S., Fagerberg B., Hjalmarson A., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 38 (2001) 932-938
27. Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
28. Swedberg K., Bristow M.R., Cohn J.N., et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105 (2002) 1797-1803
29. Mann D.L., McMurray J.J.V., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
30. Kelland N.F., and Webb D.J. Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 93 (2007) 2-4
31. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297 (2007) 1319-1331
32. Arab S., Gramolini A.O., Ping P., et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 48 (2006) 1733-1741
33. Lewis G.D., Ru W., Liu E., et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118 (2008) 3503-3512